By Michael Dabaie

 

Roche Holding AG's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.

GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessels.

This approval is the first pediatric indication for Rituxan, Genentech said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 27, 2019 14:17 ET (18:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Roche (QX) Charts.